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Abstract
Background: Tuberculosis and HIV co-epidemics are problems in many parts of the world. Xinjiang is a high
tuberculosis and HIV prevalence area in China. We aimed to investigate the prevalence and cure rate of tuberculosis
among HIV positive patients in Xinjiang.
Methods: In a retrospective study between 2006 and 2011, clinical and laboratory data on 333 patients with HIV
and tuberculosis were compared to 2668 patients with HIV only. There were 31 HIV positive patients with no data
on tuberculosis.
Results: The prevalence of tuberculosis co-infection among the HIV positive patients was 11% (95% CI 10–12%),
significantly higher than the national figure in China of 2%. In most cases HIV was diagnosed late, with advanced
immunodeficiency. The use of isoniazid preventive therapy was only 57.9% in patients without tuberculosis who
fulfilled the criteria for receiving this prevention. The cure rate one year after diagnosis was 69.2%, which was lower
than the officially reported 91.4% in all tuberculosis cases in Xinjiang in 2011. The hazard of not surviving over the
five years was significantly higher in patients with HIV + tuberculosis compared to HIV only after adjusting for sex
and Intravenous drug use with HR = 1.84 (95% CI 1.43-2.35; p < 0.0001).
Conclusions: The prevalence of tuberculosis among HIV positive patients in Xinjiang was higher than in China
taken as a whole, and HIV was diagnosed late, with underuse of isoniazid preventive therapy. The low cure rate and
reduced survival can be due to late diagnosis of HIV and no testing for antibiotic resistance, together with
insufficient control of adherence to the treatment regimens for tuberculosis and HIV.
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Background
Mycobacterium tuberculosis (TB) and human immune
deficiency virus (HIV) infections are major public health
problems in many parts of the world, particularly in low
and middle-income countries [1, 2]. In 2013, an esti-
mated 9.0 million people developed TB and 1.5 million
died from the disease. Of these, about 1.2 million (14%)
had a HIV co-infection [3]. China has the world’s second
largest number of tuberculosis cases after India (12 and
26% of global cases, respectively) in 2012 [4]. WHO
estimated the prevalence of TB (including HIV + TB) in
China 2012 to be 1,400,000 (1,200,000–1,600,000). The
incidence rate of new TB infections was 99 (86–113)/
100,000 [4].
Several studies have indicated that TB co-infection
increases the risk of HIV progression and death, particu-
larly in persons with untreated HIV [5].
HIV infection is associated with immunosuppression,
which in turn increases the risk of latent TB infection
developing into active TB [6, 7].
After contact with tuberculosis bacteria, patients with
HIV have 20 times the normal incidence of TB [8]. This
risk can be reduced by isoniazid preventive therapy
(IPT), with benefits for both the individual and for the
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further spread of TB, and it is generally accepted that
the lifetime risk of TB reactivation in the HIV positive
group can be reduced from about 30 to 4%[9, 10].
HIV positive patients with TB and low CD4+
T-lymphocyte counts (<100 cells/mm3), more often
present with atypical chest X-rays and negative acid-fast
bacilla (AFB) sputum smears, compared to HIV-negative
patients [11].
Xinjiang Uygur Autonomous Region is a province in
the Northwestern part of China, with 21,815,815 inhabi-
tants in 2011. The incidence of TB in Xinjiang was
2003–2008 estimated at 463 cases per 100,000 persons
per year [12]. The information on the prevalence of
multidrug-resistant (MDR) and extensively drug-
resistant (XDR TB) remains scant in the region, due to
TB drug susceptibility testing (DST) not being imple-
mented as a routine test at most hospitals. It was
performed in combination with a clinical study in
Urumqi from 2009 to 2011, and indicated a prevalence
of MDR TB of 13.2% [13].
One study from January 2007 to June 2010, including
11 counties in Xinjiang, reported that the HIV screening
rate was 79.1% in the TB patients’ group, and the rate of
positive HIV was 2.2% among those tested. TB was
tested for in 85.3% of the HIV positive patients, of whom
10.8% were diagnosed with TB [14].
At screening for HIV among patients with tuberculosis
in the 15 counties in Xinjiang 2007, the prevalence was
1.2% [15]. At the TB hospital, Urumqi, all patients with
TB were tested for HIV between 2009 and 2012. 6.2% of
the TB patients were co-infected with HIV, with stable
prevalence rates over time.
The availability of HIV testing in Xinjiang was not the
same the whole time period and many times offered in
projects directed towards high risk groups. In Xinjiang
the HIV infection prevalence in the drug users was
21.4% from one study 2010 [16].
Objectives
The objectives of the study were to investigate the pre-
vention, prevalence, and cure rate of tuberculosis among
HIV-positive patients in Xinjiang, China.
Methods
A cross-sectional retrospective study was carried out
between November 2006 and December 2011, and iden-
tified 3032 HIV-positive patients at the HIV clinics of
three city hospitals in Xinjiang, China. The patients were
treated in Urumqi (729), Yili (1861) and Kuqa (442). The
total populations in the three cities were respectively
3.11 million (2011), 515,000 (2011) and 475,000 (2010).
Doctors and nurses specializing in infectious diseases
at these hospitals were responsible for the collection of
data. Register forms were used to collect data on demo-
graphic factors and clinical features.
The 2001 revised diagnostic criteria for the diagnosis
and treatment of pulmonary tuberculosis were used [17]:
1. Positive culture of Mycobacterium tuberculosis from
sputum, tissue, blood, liver, spleen, lymph nodes, biopsy
or pleural effusion. 2. Persistent high fever (>38.5 °C)
more than two weeks, or night sweats, or more than
10% weight loss (3–6 months),or weakness. 3. Positive
tuberculin test (PPD), where the scleroma was moderate
(10–19 mm) or intense (>20 mm), or with blister, local
necrosis, lymphangitis). 4. Chest X-ray image showing
changes typical of tuberculosis. Patients fulfilling the first
criterion, or two of the others, were diagnosed with TB.
All the patients, irrespective of whether they had signs
and symptoms of chest infection, were screened for pul-
monary TB by chest X-ray, and then by examination of
sputum for AFB using standard techniques. Blood sam-
ples were collected periodically every 6 months and tests
included a CD4 cell count. Routine blood tests included
red blood cells, white blood cells, platelet count and
hemoglobin. HIV viral loads were not routinely
analyzed.
Patients with CD4+ T lymphocyte count <350 /μl, or
CD4+ T lymphocyte count >350 /μl together with one
of the following symptoms were eligible for anti-
retroviral treatment: enlarged lymph nodes,persistent
fever for several months, night sweats, more than 10%
weight loss, diarrhea, generalized herpes infection, oral
Candida albicans infection.
The first line antiretroviral treatment (ART), given was
two nucleoside reverse transcriptase inhibitors (NRTIs)
plus a non-nucleoside reverse transcriptase inhibitor
(NNRTIs) as combination therapy. The available first
line drug combinations were: zidovudine (AZT) + lami-
vudine (3TC) + nevirapine (NVP), AZT + 3TC+ efavirenz
(EFV) or stavudine (D4T) + 3TC+ NVP. The second line
treatments were tenofovir (TDF) + 3TC + lopinavir
(LPV) or TDF + 3TC + EFV. The drugs were supplied by
the state free of charge.
In China, the National TB Control Program (NTP) is
implemented directly through a network of TB centers
and TB hospitals, and is also used at HIV clinics [18].
Tuberculosis drug treatment is generally given according
to a standard scheme: H (isoniazid),R (rifampicin), Z
(pyrazinamid), E (ethambutol) for 3 months, then
reduced to isoniazid and rifampicin for an additional
3 months. Some patients (like patients with TB meningi-
tis, or chest X-ray without improvement) were given ex-
tended treatment for 9 months or one year. The HIV
positive patients treated at the HIV clinics were
followed-up in the actual study. For the HIV negative
patients treated at the TB centers and TB hospitals, we
have no data on adherence to treatment or follow-up
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programs, and only reports of case fatalities. We have no
information about whether the patients in our study had
been treated at TB centers previously.
HIV positive patients with CD4 < 100/μl were recom-
mended IPT. In addition, patients with CD4 < 250/μl
together with weight loss, lymph node enlargement or
PPD where the scleroma was 5–10 mm, were recom-
mended IPT.
In this study, no patient underwent the TB resistance
test, because it was not available at the general hospitals
in Xinjiang. The study from between 2009 and 2011 on
the prevalence of MDR-TB [13] did not include the
patients in this study.
During the treatment, the patients were monitored for
CD4 cell count, levels of liver enzymes, chest X-ray in
cases with lung symptoms like cough or sputum.
Statistical methods
For comparison of proportions between groups we used
Chi-square test. The differences in hazard between
groups were analyzed by Cox proportional hazard ana-
lysis. Survival curves based on Kaplan-Meier estimates
are presented. P-values < 0.05 were regarded statistically
significant.
We analyzed the cure rate one year from the diagnosis
of TB. We defined a TB cure as patients surviving the
treatment period, having a negative sputum smear if pre-
viously the smear was positive, no remaining TB- related
symptoms, and an improvement in chest or extrapul-
monary X-ray findings, and no relapse after the end of
TB treatment, relapse was defined as having a positive
culture 30 days after the last treatment date [19].
Patients who stopped treatment before full term and
patients lost to follow-up were regarded as treatment
failures. Patients who transferred to other clinics, and
surviving patients followed for less than one year, were
excluded from the analysis of cure rate.
Results
The flow chart describing the included patients in the
study is shown in Fig. 1.
Sociodemography
The demographic data on the patients with HIV + TB
and HIV only are shown in Table 1.
The prevalence of TB among the HIV positive patients
was 333/3032 (11%), it was higher in men than in
women (14% vs 7%, p < 0.05).
For the patients with extra-pulmonary TB (EPTB) the
mean age was 39.2 years (median 38, range 27–52).
The main route of the HIV infection among patients
with HIV + TB was Intravenous Drug Use (IVDU) at
58.3% (95% CI 53–63.6), which was significantly higher
than for patients with HIV only, at 38.9% (95% CI 37.1-
40.7); p <0.05.
Of the patients with HIV + TB, 72.7% (95% CI 68–
77.4) were men, which was significantly higher than for
patients with HIV only where the figure was 55.3% (95%
CI 53.4-57.2).
Hepatitis B surface antigen (HBsAg) was positive in 21
(6%) of all 333patients with HIV + TB, with 14/21 (67%)
being HBV-DNA positive. Hepatitis C antibodies were
Fig. 1 Flow chart detailing recruitment and TB presentation
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found in 83 (25%) of the 333 patients, and 33/83 (40%)
were HCV-RNA positive.
Among the 1247 IVDUs 38% were HBsAg positive and
40% were HCV- RNA positive. Data on treatment for
hepatitis were not registered, but treatments were not
free and it is likely most patients were untreated.
Clinical symptoms
The symptoms among patients with HIV + TB and HIV
without TB are shown in Table 2. As shown, fever,
cough, sputum production and night sweats were more
common in the HIV + TB patients.
The average CD4 count at the time of HIV diagnosis
was 169/μl in patients with HIV + TB, (median 146/μl;
range 2–931), compared to 230/μl (median 223, range
1–1668) in the patients without TB. Out of the patients
with HIV + TB 51.1% (95% CI 45.8-56.4) had CD4
counts of less than 150, which was significantly more
common than in patients with HIV only, at 35.2% (95%
CI 33.4-37).
Thirty-eight patients (11.4%) had EPTB, of which 28
(74%) were men. The largest proportion of EPTB cases
had tubercular lymphadenitis (53%), followed by pleural
tuberculosis (18%).
Treatment of tuberculosis and HIV
Of the 333 patients with TB, 292 (87.7%) received treat-
ment for TB. Six surviving patients had less than one
year of follow-up, 7 (2.4%) were lost to follow up, and 4
(1.4%) were transferred to other clinics. Among the
remaining 275 patients, 256 (93.1%) started the TB treat-
ment before the ART. But we have no any details re-
garding reasons for stopping treatment and for being
lost during follow-up period.
Isoniazid preventive therapy
Among the 1161 patients without TB who fulfilled the
criteria for IPT, it was given to 57.9% during the study
period. Patients with intravenous drug use (IVDU) had
lower rates of IPT 51.4% (95% CI 47.7-55.1) than non-
IVDU patients, where 63.1% (95% CI 59.4-66.8) received
the treatment. Men had a lower rate of IPT at 53.7%
(95% CI 50–57.4), than women, at 64.5% (95% CI 61–
68). Of the IVDU patients, 93.9% were men. No statisti-
cally significant difference was seen between ethnic
groups, see Table 3.
Cure rate and survival
In our study the cure rate one year after diagnosis of TB
could be evaluated for 234 patients and was 162/234
(69.2%). Twenty-three other patients (9.8%) had im-
proved. No improvement in symptoms was seen among
18 patients (7.7%) and 31 (13.2%) had died. The causes
of death were unfortunately not registered.
The survival time of HIV + TB patients was signifi-
cantly shorter than in the patients with HIV only (Fig. 2).
We note that reduced survival time among the patients
with TB was marked during the first year, with no add-
itional reduction of survival the following years (Fig. 2).
The hazard of not surviving over the five years was
significantly higher in patients with HIV + TB com-
pared to HIV only after adjusting for sex and IVDU
with HR = 1.84 (95% CI 1.43-2.35; p < 0.0001).
For the patients with IVDU there was no significantly
different survival the first year. However, during the fol-
lowing years, this group had reduced survival rates year
by year starting from the second year (Fig. 3).
Among the 333 patients with HIV + TB data on
other opportunistic infections were available for 275
patients. The surviving 203 patients had a median
time of follow-up on 39 months. Out of them 21





Sex Men 242 1492
Women 91 1176














No data 18 160
CD4 <100 122 492
100-249 138 1083
>250 71 1118
No data 2 6
Opportunistic
infections
Oral candida infection 33 49
PCP 11 6
Oral hairy leukoplakia 2 16
KS 4 14
Generalized herpes infection 12 48
Others 9 27
Abbrevations: IVDU (intravenous drug users), MTCT (mother-to- child
transmission), PCP (Pneumocystis Jiroveci pneumonia), KS (Kaposis Sarkoma)
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(10.3%; 95% CI 6.2-14.4%) had one or more previous
or actual opportunistic infections (10 oral candida in-
fection,6 generalized herpes infection, 2 Pneumocystis
jiroveci pneumonia (PCP), 2 oral hairy leukoplakia, 1
Kaposi sarcoma.). Among 72 patients who had died,
16 had oral candida, 3 generalized herpes infection, 5
PCP, 2 Kaposi sarcoma. The rate of opportunistic
infections in dead patients was 26/72 (36% (95% CI
24-47%), statistically significantly higher than among
the surviving patients.
Discussion
The prevalence of TB co-infection in the HIV positive
patients in Xinjiang was 11% (95% CI:10–12%), which
was significantly higher than the national figure in China
of 2% [4] in 2012 and also tended to be higher than in a
study from Tanzania on 340 women coming to voluntary
counselling and testing (VCT) center for HIV test with a
figure of 5.3%(95% CI:0–10.6%) [20]. In this study, we
found that the higher prevalence of HIV + TB in men on
14% compared to 7% in women (p < 0.05). This could be
due to the fact that 67.5% of the men and only 5.9% of
the women were IVDU. TB/HIV co-infection was more
prevalent in men also in a Tanzanian study [20], but in
Tanzania there were not many IVDUs, but alcohol abuse
was common among men.
Out of the patients in our study, 87.7% of patients co-
infected with HIV and TB started treatment for both
HIV and TB. This is a better figure than for China as a
whole, where it is reported that only 23% of TB patients
were tested for HIV in 2011 with 4715 (2%) being HIV
positive. Of these, only 1677 (36%) received ART [21].
More than half of the patients with HIV +TB (51.1%) had
CD4 counts of less than 150, which was significantly more
common than in patients with HIV only, at 35.2%. It indi-
cated a late diagnosis of HIV among the patients with TB.
Among the 1161 patients fulfilling the criteria for
isoniazid prophylaxis, only 57.9% received the prophy-
laxis. Men had lower rate for prophylaxis treatment than
women in our study. This could due to the fact that
most of IVDUs were men, for whom preventive
treatment is more difficult.
Extrapulmonar tuberculosis (EPTB) was seen among
11.4% (95% CI:8.1-14.4) of patients in our study, which
Table 2 Symptoms among patients with HIV + TB, and HIV only
HIV/PTB N = 295
n (%; 95% CI)
HIV/EPTB N = 38
n (%; 95% CI)
HIV + TB N = 333
n (%; 95% CI)
HIV only N = 2668
n (%; 95% CI)
Fever 125 (42.4; 36.7-48.1) 12 (32; 17.1-46.9) 137 (41.1; 35.8-46.6)* 392 (14.7; 13.3-16.1)*
Cough 142 (48.1;42.4-53.8) 7 (18; 5.8-30.2) 149 (44.7; 39.4-50)* 472 (17.7; 16.3-19.1)*
Productive cough with sputum 116 (39.3;33.8-44.8) 5 (13; 2.2-23.8) 121 (36.3;31.2-41.4)* 389 (14.6; 13.2-16)*
Dyspnea 28 (9.5;6.2-12.8) 4 (11; 1–21) 32 (9.6; 6.5-12.7)* 107 (4.0; 3.3-4.7)*
Sternalgia 41 (13.9;10–17.8) 3 (8; 0–16.6) 44 (13.2; 9.7-16.7)* 104 (3.9; 3.2-4.6)*
Night sweats 116 (39.3;33.8-44.8) 11 (29; 14.5-43.5) 127 (38.1; 32.8-43.4)* 344 (12.9; 11.6-14.2)*
Diarrhea 22 (7.5;4.5-10.5) 4 (11; 1–21) 27 (8; 5–11) 253 (9.5; 8.4-10.6)
Nausea 27 (9.0;5.7-12.3) 2 (6.0; 0–13.4) 28 (8.4; 5.4-11.4) 240 (9.0; 8–10)
Projectile vomiting 3 (1.0;0–2.1) 2 (6.0; 0–13.4) 3 (1.0; 0–2.1) 27 (1.0; 0.6-1.4)
Headache 38 (12.9;9.2-16.6) 2 (6.0; 0–13.4) 40 (12.0; 8.5-15.5) 312 (11.7; 10.5-12.9)
Blurry vision 16 (5.4;2.9-7.9) 1 (3; 0–8.5) 17 (5.1; 2.7-7.5) 179 (6.7; 5.8-7.6)
Rash 12 (4.1;2.1-6.1) 2 (6.0; 0–13.4) 14 (4.2; 2.2-6.2) 115 (4.3; 3.5-5.1)
Lymphadenectasis 34 (11.5;7.8-15.2) 11 (29; 14.5-43.5) 45 (13.5; 9.8-17.2)* 160 (6.0; 5–7)*
*P < 0.05
Table 3 Isoniazid preventive therapy (IPT) for patients fulfilling
the criteria for IPT
fulfilling the criteria
for IPT (n = 1161) N
IPT (n = 672)
N (%; 95% CI)
All 1161 672
Men (n = 1734) 713 383 (53.7;50–57.4)
Women (n = 1298) 448 289 (64.5;61–68)
Uygur (n = 2560) 992 571 (57.6;53.9-61.3)
Han (n = 338) 124 72 (58.1;54.4-61.8)
Other (n = 134) 45 29 (64;60.5-67.5)
IVDU (n = 1247) 519 267 (51.4;47.7-55.1)
Non-IVDU (n = 1785) 642 405 (63.1;59.4-66.8)
Ongoing follow-up
(n = 2107)
670 527 (78.7; 75.7-81.7%)
Stop-ART (n = 367) 125 42 (33.6;30.1-37.1)
Death (n = 426) 280 70 (25;21.7-28.3)
Lost follow-up
(n = 106)
77 27 (35; 24–46)
Transferred (n = 25) 9 6 (67)
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is similar to the global figure of 13% on all TB cases re-
ported by WHO [22], but low compared to what is seen
in study with 757 patients with HIV in Ethiopia with
25% (95% CI:19.7-30.3) [23]. We found that in our cases
the most common types of EPTB were lymphadenitis
(53%) and pleural TB (18%). Peto et al. published a wide
series of EPT cases from the USA and revealed that
lymphatic (40%) and pleural (19.8%) types of EPTB were
the most frequent, and meningeal involvement was
found in 5.4% of their cases [24].
The cure rate of TB in our study was 162/234 (69.2%)
(95% CI 66.2–72.2%), lower than the officially reported
91.4% for all cases of TB in Xinjiang 2011 [25], but simi-
lar as results of a study from Zimbabwe with 225 adult
TB patients with a figure of 70% (95% CI 50–90) [26].
The cure rate for EPTB was 34.2%. There is no previ-
ously reported data from Xinjiang, but results are similar
to those of a study from Taiwan of 28.7% [27]. Mortality
among patients with EPTB was 36.8% in our study,com-
pared to 14.7% in a study from the United States [28].
Low TB cure rates among patients with HIV can be due
to late HIV diagnosis with advanced immunodeficiency
and no testing of TB resistance. Insufficient control of
adherence to treatment regimens makes it impossible to
evaluate if this can be a cause of the low cure rates. Both
the treatment of TB and HIV need a high level of adher-
ence to be successful.
According to WHO estimates, approximately 1 million
new TB cases and 54,000 MDR-TB cases in 2013 [29]
occur in China, Xinjiang is one of the areas in China
with the highest prevalence [13]. The incidence of drug
resistance is higher in the north, west, and central areas
of China, and lower in south and east China [30–32].
However, testing for resistance was not performed in
Xinjiang during the studied period, which blocked opti-
mal treatment and control of TB.
Rapid and timely detection of TB cases and strength-
ened capacity to diagnose cases of drug-resistant TB are
thus global priorities for TB care and control [7]. The
Gene Xpert MTB/RIF test on sputum can in about 2 h
detect 73% of culture positive acid fast bacilla (AFB)
smear- negative TB cases from one specimen, and 90%
after three specimens in the study by Boehme et al. in
study from Peru, Azerbaijan, South Africa, and India
[33]. In a study in Ethiopia Gene Xpert had a sensitivity
on culture- positive smear-negative TB cases of 57.4%
with one sputum sample and 67.6% with two samples
[34]. That and similar tests could allow for more rapid
detection of tuberculosis and drug resistance outside
reference centers, and cut delays in diagnosis, without
the need to build large numbers of laboratories equipped
to meet advanced biosafety [33] requirements. The
problem is however the high cost.
Treatment discontinuation is considered as one of the
risk factors for MDR-TB [35–38]. Although TB control
and prevention in the Centre of Disease Control and
prevention (CDC) system have professional follow-up
systems, the patients from the hospitals are sometimes
missed at transfer from hospitals to local TB dispensar-
ies, and will thus not complete their follow-up treatment
and get a high risk of drug resistance [30].
In this study the survival time of the IVDU patients was
shorter than of non-IVDU patients. One important reason
for low survival among HIV + IVDU patients can be the
high proportion of patients with untreated hepatitis B and
C. Of the patients with IVDU 27% were HBsAg positive
and 40% were HCV-RNA positive. There was no free
treatment for hepatitis B or C in Xinjiang [39].
There are very limited economic resources in Xinjiang
compared to developed cities like Beijing, Shanghai and
Guangzhou. Although the Chinese government in recent
years has implemented a new healthcare system, there is
not enough money for patients in the whole country to re-
ceive good medical treatment from the onset of the disease.
Fig. 2 Survival time in 333 patients with HIV + tuberculosis and in 2668
with HIV only
Fig. 3 Survival time in 1247 patients with intravenous drug use
(IVDU) compared to 1353 patients with no IVDU. (For 432 patients
data were missing)
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There is also limited skill in medical treatment in most
of the rural hospitals. In addition, the patients’ living
conditions are often poor, with people crowding in the
same living spaces to reduce costs of heating.
In the case of TB symptoms, many patients did not pay
attention to them, because of lack of money. Although the
TB drug are free for tuberculosis patients, they must
afford the cost for auxiliary treatment, including drugs for
reducing adverse reactions [40]. They have to pay for
travel costs, tests and hospital care, which can discourage
them, and may in turn lead to delayed diagnosis and treat-
ment, with increased risk of spreading TB.
According to the results of a national general survey
of tuberculosis between 2001 and 2010 in China, only
47% of patients with pulmonary tuberculosis went to the
hospitals, and knowledge of TB prevention and control
was only 57% [41].
A beneficial effect of immediate antiretroviral therapy
was evident for reductions in rates of TB, Kaposi’s sar-
coma, and malignant lymphomas, meanwhile, the
significant benefit in the immediate antiretroviral ther-
apy in patients with HIV infection regardless of CD4+
count [42]. Hence, economic assistance should be
available to ensure that TB patients with economic hard-
ship can complete treatment, thus reducing the
emergence of drug-resistant TB [40].
Limitations
This study was carried out in HIV clinics from 3 hospi-
tals in Xinjiang. The data is dependent on the quality of
the patient records, and we did not include CDC clinics,
and private hospitals. For these reasons the results might
not reflect the overall TB situation in this region. We
lack data on the treatment outcomes of patients who
were transferred. We have no data on whether patients
were living in cities or rural areas. We also lack data on
the causes of death.
Conclusions
The low cure rate of TB and reduced 5- year survival in
the HIV positive patients could be caused by late diagnosis
of HIV, no availability of TB resistance tests, together with
a lack of documented high levels of adherence to HIV and
TB treatment regimens.
Hence, economic assistance should be available to ensure
that TB patients with economic hardship can complete
treatment, thus reducing the emergence of drug-resistant
TB.
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